SLIT2

Across TCGA pan-cancer cohorts, SLIT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLIT2 data layer compared with 28 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLIT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLIT2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLIT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.863	0.686	.002	36	view →
CCRCC	OS	Quartile	All	1.000	0.778	.003	17	view →
LUAD	DFS	Median	All	0.723	0.540	.042	2	view →
GBM	OS	Median	All	0.433	0.641	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLIT2–PDAC (DFS)

Open the PDAC breakdown →